Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stellar Announces Issuance of Patents for C. diff Immunotherapy Technology

Published: Tuesday, December 10, 2013
Last Updated: Tuesday, December 10, 2013
Bookmark and Share
Issuance of two additional patents in U.S. and China.

Stellar Biotechnologies, Inc. has announced the issuance of two additional patents, in the United States and in China, covering the Company’s active immunotherapy technology for the treatment of Clostridium difficile infection (“C. diff”).

Clostridium difficile is a bacteria found in the intestines that can cause severe and life-threatening intestinal conditions. C. diff infections are at an all-time high and related hospitalizations have tripled in the last decade.

The two patents, U.S. patent No. 8,597,663 and China patent No. 200880115518.2, describe certain novel cell surface polysaccharides and their chemical structures with broad claims covering antigen and vaccine compositions for the treatment, prevention and diagnosis of C. diff infection.

Stellar holds the exclusive, worldwide rights to develop, manufacture and sell human vaccines and other products derived from these patents, licensed from the University of Guelph. The license covers intellectual property related to the cell-wall polysaccharide of C. diff named PSII.

Stellar’s technology combines PSII with Stellar KLH™ into an active immunotherapy approach with potential advantages over other technologies.

“Our PSII-KLH technology is dramatically different from other approaches,” said Herbert Chow, Ph.D., Stellar’s Chief Technology Officer. “We are harnessing the body’s own immune system to disrupt the fundamental pathways of C. diff pathogenesis and transmission, unlike many methods which can only impact disease symptoms. These patents strengthen Stellar’s intellectual property and further raise the barriers around our C. diff platform.”

The novel combination of PSII-KLH is designed to activate innate and adaptive immune systems in the intestines that directly inhibit spore germination and reduce bacterial burden.

In this way, Stellar’s PSII-KLH vaccine is cell-directed to limit the extent and spread of disease transmission. Preliminary preclinical studies from Stellar’s PSII-KLH active immunotherapy program demonstrated protection against C. diff in mice.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Stellar Signs Collaboration Agreement to Expand KLH Aquaculture Operations
Stellar secures strategic site in Mexico for exclusive sustainable KLH production.
Wednesday, August 12, 2015
Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship
Companies sign KLH supply agreement for Neovacs' Kinoid clinical trials and initial commercialization.
Saturday, April 04, 2015
Stellar and Araclon Biotech Sign Exclusive KLH Supply Agreement
Exclusive supply agreement for clinical trials in Alzheimer's active immunotherapies.
Wednesday, November 12, 2014
Stellar and Biovest Sign KLH Supply Agreement
Agreement for BiovaxID immunotherapy for follicular non-Hodgkin's lymphoma.
Tuesday, November 04, 2014
Stellar Biotechnologies Appoints Two Members to SAB
Appointment of Gregory T. Baxter and Charles V. Olson to the Company's Scientific Advisory Board.
Saturday, June 07, 2014
Stellar Biotechnologies Launches New Corporate Website
The new website showcases Stellar's Core KLH products, breakthroughs in aquaculture science, and strategic expansion of its immunotherapy program in a user-friendly platform.
Thursday, May 08, 2014
Stellar Issues Year-End Results and Highlights from 2013
Company announces financial results and operational highlights for 2013.
Friday, January 03, 2014
Stellar Announces Collaboration with Amaran Biotechnology, Inc.
Collaboration agreement to develop and evaluate methods for the manufacture of OBI-822 active immunotherapy.
Friday, December 13, 2013
Stellar Expands Senior Leadership Roles with Two Key Appointments
Appointment of Kathi Niffenegger and Catherine Brisson as CFO and COO respectively.
Wednesday, November 06, 2013
Stellar Presents Preclinical Poster on C. diff Active Immunotherapy
Poster presented at 7th Vaccine and ISV Congress being held in Spain.
Tuesday, October 29, 2013
Stellar’s Immunotherapy Technology Demonstrates Protection Against C. diff Infection
Study results presented this week at ClostPath 8 in Australia, October 22-26, 2013.
Tuesday, October 22, 2013
Stellar Appoints Tessie Che, Ph.D. to Board of Directors
Dr. Che is currently Chair of the Board of Directors of Amaran Biotechnology.
Thursday, September 26, 2013
Stellar Acquires Exclusive, Worldwide License to C. diff Immunotherapy Technology
Stellar expands with proprietary KLH-based vaccine program.
Wednesday, July 31, 2013
Stellar Biotechnologies Exceeds Aquaculture Capacity Goals
Facility expansion and cultivation innovations ensure supply leadership.
Tuesday, July 23, 2013
Stellar Biotechnologies Presents at Annual 2013 NSF Conference
Poster titled “Megathura crenulata Post Larval Culture - Bottleneck for a Valuable Medical Resources” was presented by Brandon Lincicum.
Friday, July 05, 2013
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!